Clinical Trial Update: A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 prospective, one-arm open trial evaluating obinutuzumab for immune thrombocytopenia, currently recruiting in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: RECRUITING